Free Trial

Precipio Q1 2024 Earnings Report

Precipio logo
$5.27 -0.08 (-1.50%)
(As of 12/20/2024 05:16 PM ET)

Precipio EPS Results

Actual EPS
-$1.46
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Precipio Revenue Results

Actual Revenue
$3.43 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Precipio Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

Precipio Earnings Headlines

Precipio Reports Improved Financials Amid Challenges
Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript
Precipio Announces Q3-2024 Shareholder Update Call
See More Precipio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precipio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precipio and other key companies, straight to your email.

About Precipio

Precipio (NASDAQ:PRPO), a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

View Precipio Profile

More Earnings Resources from MarketBeat

Upcoming Earnings